Skye Bioscience, Inc. (SKYE)
$1.53-3.16%Close
SELLCRISIS · day 56
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $54M
- Beta
- 2.86
- P/E (TTM)
- -0.15
- Short % float
- 0.64%
- Days to cover
- 1.7
- SI change
- +26.4%
- 1W
- -5.56%
- 1M
- -23.12%
- vs SPY 1W
- -5.42%
- vs SPY 1M
- -25.62%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 7
- VALUE
- 13
- GROWTH
- 35
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-197.4%
REV YoY-
ROE-329.1%
EPS YoY-
ROA-457.6%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.15
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-15.26
P/FCF-
EV/EBITDA0.03
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.95
ND/EBITDA-
BETA2.86
Company news
FAQ
- What is LOPJLB’s current signal on SKYE?
- LOPJLB’s latest quantitative signal on Skye Bioscience, Inc. (SKYE) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SKYE in?
- Skye Bioscience, Inc. (SKYE) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Skye Bioscience, Inc. (SKYE) do?
- Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company …